Edited by Lu HM
Published online Feb 15, 2002. doi: 10.3748/wjg.v8.i1.99
Revised: October 22, 2001
Accepted: October 29, 2001
Published online: February 15, 2002
AIM: To examine the molecular mass and identify the bioactivity of MG7 scFv for its application as a targeting mediator in gene therapy of gastric cancer.
METHODS: Two strongly positive recombinant phage clones screened from MG7 recombinant phage antibody library were separately transfected into E.coli TG1. Plasmid was isolated from the transfected E.coli TG1 and digested by EcoR I and Hind III to examine the length of exogenous scFv gene. Then, the positive recombinant phage clones were individually transfected into E.coli HB2151.The transfectant was cultured and induced by IPTG. Perplasmic extracts was prepared from the induced transfectant by osmotic shock. ELISA was used to examine the antigen-binding affinity of the soluble MG7 scFv. Immunodoting assay was adopted to evaluate the yield of soluble MG7 scFv produced by transfected E.coli HB2151. Western blot was used to examine the molecular mass of MG7 scFv. Finally, the nucleotide sequence of MG7 scFv was examined by DNA sequencing.
RESULTS: two positive recombinant phage clones were found to contain the exogenous scFv gene. ELISA showed that MG7 scFv had strong antigen-binding affinity. Immuodoting assay showed that transfected E.coli HB2151 could successfully produce the soluble MG7 scFv with high yield via induction by IPTG. The molecular mass of MG7 scFv was 30 kDa by western blot. DNA sequencing demonstrated that the VH and VL genes of MG7 scFv were 363 bp and 321 bp, respectively.
CONCLUSION: We have successfully developed the soluble MG7 scFv which possessed strong antigen-binding affinity.
- Citation: Yu ZC, Ding J, Pan BR, Fan DM, Zhang XY. Expression and bioactivity identification of soluble MG7 scFv. World J Gastroenterol 2002; 8(1): 99-102
- URL: https://www.wjgnet.com/1007-9327/full/v8/i1/99.htm
- DOI: https://dx.doi.org/10.3748/wjg.v8.i1.99
Gastric cancer takes the leading place in the incidence of various tumors in china. Many conventional approaches, including surgical, chemical and physical treatments, appear palliative in most advanced cases. Because these conventional approaches cannot selectively target at the tumor cells and completely eradicate them, and recurrence and metastasis of tumor may develop due to the existence of residual tumor cells. Therefore, targeting therapy for tumor is badly needed to achieve a greater curative effect and overcome the obstacle existing in the conventional approaches[2-13]. Recent studies showed that the targeting therapy had a promise in the treatment of gastric cancer[14-29]. In the present study, we produced the soluble MG7 scFv and evidenced that MG7 scFv is a favorable mediator for targeting therapy of gastric cancer.
The strong positive recombinant phage clones (3 µL containing 2 × 10 9 pfu) were separately added into 5 mL log-phase E.coli TG1 and incubated for 1 h at 37 °C with shaking at 250 r·min-1. Plasmid was isolated from the culture product and digested by EcoR I and Hind III. Electrophoresis was performed to check the digested product.
The strongly positive recombinant phage clones (3 µL containing 2 × 109 pfu) were separately added into 5 mL log-phase E.coli HB2151 and incubated for 1 h at 37 °C with shaking at 250 r·min-1. 10 µL IPTG (isopropyl β-D-thiogalactopyanoside) were added and incubated overnight at 37 °C with shaking at 250 r·min-1. Cells were precipitated by centrifugation and supernatant was also collected. The precipitated cells were subjected to osmotic shock for preparation of soluble MG7 scFvs. KATOIII cells in log phase were transferred into a 96 wells-plate and immobilized on the wall by centrifiguation at 1000 g for 10 min, and finally fixed in 0.25 mL·L-1 glutaraldehyde. 0.2 mL perplasmic extracts and supernatant were applied to each well and incubated at 4 °C overnight. 0.2 mL anti-E tag antibody were applied to each well and incubated at 37 °C for 2 h. 0.1 mL HRP-labeled goat anti-mouse (HRP-GAM) Ig solution was added into each well. The absorbance value (A) at 450 nm of reactant in each well was measured after incubation for 1 h at 37 °C and staining with TMB.
40 µL of perplasmic extracts and supernatant were separately dotted on the Hybond-C super membrane and dried at 60 °C for 30 min. After being blocked by 50 mL·L-1 nonfat milk for 2 h, the Hybond-C super membrane was incubated in 5 mL diluted anti-E tag antibody solution at 37 °C for 2 h. 5 mL HRP- labeled goat anti-mouse (HRP-GAM) Ig solution were added for another incubation at 37 °C for 1 h and eventually stained by DAB.
40 µL of perplasmic extracts and supernatant were firstly analysized by SDS-PAGE and then transferred onto the Hybond-C super membrane. After being blocked by 50 mL·L-1nonfat milk, the Hybond-C super membrane was incubated in 5 mL diluted anti-E tag antibody solution at 37 °C for 2 h. 5 mL of HRP- labeled goat anti-mouse (HRP-GAM) Ig solution were added for another incubation at 37 °C for 1 h and eventually stained by DAB.
DNA sequencing was performed by ABI PRISMTM 377 DNA sequencer.
Two strongly positive clones were found to be recombinant clones which contained the exogenous gene. One of the two strongly positive clones contained a 450 bp fragment of exogenous gene (Lane 1)and the other one contained a 750 bp fragment of exogenous gene(Lane 2, Figure 1).
One of the strong positive clones was shown to produce soluble form of MG7 scFv with Antigen-binding activity (Table 1). This clone was confirmed to contain a 750 bp fragment of exogenous gene by restriction analysis above and chosen for later use.
|ELISA||Number of strong positive clones||Neg. ctrl|
The positive signal displayed on the dotting site with perplasmic extracts from induced E.coli HB2151 was significantly stronger than that from non-induced E.coli HB2151 (Figure 2). It implied that E. coli HB2151 had successfully produced the soluble MG7 scFv via induction by IPTG.
A protein band with positive signal was found at Mr 30 indicating that the soluble MG7 scFv was a protein of Mr 30 (Figure 3).
The VH and VL genes of MG7 scFv were respectively 363 bp and 321 bp in length. The VH gene has two conserved codon for cysteine at 67-69 bp and 289-291 bp.The VL gene has two conserved codon for cysteine at 472-474 bp and 664-666 bp. Both of the VH and VL genes are highly homologous with the variable fragment of some known antibodies (Figure 4).
MG7, a monoclonal antibody against human gastric cancer, was proved to possessa quite high specificity and sensitivity to gastric cancer associated antigen. It was successfully used in experimental targeting therapy in nude mice bearing transplanted human gastric cancer. But owing to its murine origin, like many other similar antibodies, MG7 antibody can elicit anti-mouse immunoreaction in man and thus its use in clinical practice is restricted[31,32]. One of the efficient strategies to this problem is to remove the constant region of antibody which makes main contribution to the immunogenicity of the murine antibody to human being[33-38]. On the other hand, antibody without constant region, termed scFv, is less antigenic and induces weaker repulsive reaction. In addition, it is a smaller molecule and comprises 1/6 of its original antibody in molecular mass which ensure that scFv can more readily penetrate into the tumor tissue in vivo and be easily cleared up from the normal tissue[39,40]. Besides, the scFv is more available than its original antibody by gene engineering technology which can provide an economical means for diagnosis of gastric cancer[41-47].
As mentioned above, the scFv is advantageous to its original antibody in clinical practice. Therefore, developing the MG7 scFv is of great significance in both early diagnosis and therapy of gastric cancer. For example, MG7 scFv fused with avidin can be used as a reagent in immuno-PCR for early diagnosis of gastric cancer. Additionally, a new immunotoxin for treatment of gastric cancer can be developed by fusing the MG7 ScFv and A subunit of ricin together. MG7 ScFv can direct the A subunit of ricin to MG7 positive gastric cancer cells[48-50]. In our previous study, the MG7 recombinant phage antibody derived from MG7 hybridoma was constructed and subsequently two strong positive phage antibody clones were screened out from this library.
Targeting therapy for tumors in the last decade has become a highlight in the field of tumor therapy[52-57]. In past, the discoveries of many tumor specific antigen (TSA) and tumor associated antigen (TAA) assured the practicability of antibody as a tool in tumor targeting therapy[58-69]. Ascribed to its high specificity and sensitivity in recognizing associated antigen, antibody is the optimal candidate for targeting mediator. Therefore, targeting therapy mediated by antibody still remains as a promising curative modality among the ways of tumor therapy and attracts worldwide attention.
This study was conducted with the purpose to produce the soluble MG7 scFv, identify its antigen-binding affinity, determine its molecular mass and get an understanding of its nucleotide sequence. We first examined the length of exogenous MG7 scFv gene harbored in the two strong positive phage antibody clones by restriction analysis and found that one of the phage antibody clones contained a 750 bp fragment of exogenous gene which was identical to many discovered scFvs in length. Secondly, we prepared the perplasmic extracts (containing majority of the soluble scFv ) from IPTG-induced E.coli HB2151 and detected the antigen-binding affinity of MG7 scFv by ELISA. One of the soluble MG7 scFvs was shown to possess apparent antigen-binding activity. Subsequently, immunodoting test exhibited that E.coli HB2151 had successfully produced the soluble MG7 scFv with high yields via induction by IPTG. Meanwhile, western blot suggested that the molecular mass of soluble MG7 scFv was Mr 30. Finally, DNA sequencing unraveled that the MG7 scFv had the common characteristics shared by other known scFvs in nucleotide sequence. Collectively, we have successfully developed the soluble MG7 scFv and created an opportunity to study its application in targeting therapy of gastric cancer.
|1.||Niu WX, Qin XY, Liu H, Wang CP. Clinicopathological analysis of patients with gastric cancer in 1200 cases. World J Gastroenterol. 2001;7:281-284. [PubMed]|
|2.||Wan Z, Wang H, Jiang S. Selection of human anti-HAV McAb from a phage antibody library. Chin J Biotechnol. 1998;14:173-178. [PubMed]|
|3.||Lu XP, Li BJ, Chen SL, Lu B and Jiang NY. Effect of chemotherapy or targeting chemotherapy on apoptosis of colorectal carcinoma. Shijie Huaren Xiaohua Zazhi. 1999;7:3332-334.|
|4.||Liu HF, Liu WW, Fang DC. Induction of apoptosis in human gastric carcinoma cell line SGC7901 by anti-Fas monoclonal antibody. Shijie Huaren Xiaohua Zazhi. 1999;7:476-487.|
|5.||Ning XY, Yang DH. Research and progress is in vivo gene therapy for primary liver cancer. Shijie Huaren Xiaohua Zazhi. 2000;8:89-90.|
|6.||Chen JP, Lin C, Xu CP, Zhang XY, Fu M, Deng YP, Wei Y and Wu M. Transduction efficiency, biologic effect and mechanism of recom-binant RA538, antisense C-myc adenovirus on different cell lines. Shijie Huaren Xiaohua Zazhi. 2000;8:266-270.|
|7.||Guo SY, Gu QL, Liu BY, Zhu ZG, Yin HR and Lin YZ. Experimental study on the treatment of gastric cancer by TK gene combined with mIL-2 gene. Shijie Huaren Xiaohua Zazhi. 2000;8:974-978.|
|8.||Pan X, Pan W, Ni CR, Ke CW, Cao GW and Qi ZT. Killing effect of tetracycline-controlled expression of DT/VEGF system on liver cell cancer. Shijie Huaren Xiaohua Zazhi. 2000;8:867-873.|
|9.||Leng JJ, Chen YQ, Leng XS. Genetic therapy for pancreatic neoplasms. Shijie Huaren Xiaohua Zazhi. 2000;8:916-918.|
|10.||Pan X, Pan W, Ke CW, Zhang B, Cao GW, Qi ZT. Tetracycline controlled DT/VEGF system gene therapy mediated by adenovirus vector. Shijie Huaren Xiaohua Zazhi. 2000;8:1121-1126.|
|11.||Wang FS, Wu ZZ. Current situation in studies of gene therapy for liver cirrhosis and liver fibrosis. Shijie Huaren Xiaohua Zazhi. 2000;8:371-396.|
|12.||Pan X, Ke CW, Pan W, He X, Cao GW, Qi ZT. Killing effect of DT/ VEGF system on gastric carcinoma cell. Shijie Huaren Xiaohua Zazhi. 2000;8:393-396.|
|13.||Cao GW, Qi ZT, Pan X, Zhang XQ, Miao XH, Feng Y, Lu XH, Kuriyama S, Du P. Gene therapy for human colorectal carcinoma using human CEA promoter contro led bacterial ADP-ribosylating toxin genes human CEA: PEA & amp; DTA gene transfer. World J Gastroenterol. 1998;4:388-391. [PubMed]|
|14.||Lu XP, Li BJ, Chen SL, Lu B, Jiang NY. Anti-CEA monoclonal anti-body targeting therapy for colorectal carcinoma. Shijie Huaren Xiaohua Zazhi. 1999;7:329-331.|
|15.||Engelstädter M, Bobkova M, Baier M, Stitz J, Holtkamp N, Chu TH, Kurth R, Dornburg R, Buchholz CJ, Cichutek K. Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library. Hum Gene Ther. 2000;11:293-303. [PubMed] [DOI]|
|16.||Wu YD, Song XQ, Zhou DN, Hu XH, Gan YQ, Li ZG, Liao P. Experimental and clinical study on targeting treatment of liver can-cer using radionuclide- anti-AFP antibody -MMC doubllet. Shijie Huaren Xiaohua Zazhi. 1999;7:387-390.|
|17.||Zhang J, Liu YF, Yang SJ, Sun ZW, Qiao Q and Zhang SZ. Construc-tion and expression of mouse/humanized ScFv and their fusion to humanized mutant TNF ¦Á against hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi. 2000;8:616-620.|
|18.||Chen ZN, Bian HJ, Jiang JL. Recent progress in anti-hepatoma mono-clonal antibody and its application. Shijie Huaren Xiaohua Zazhi. 1998;6:461-462.|
|19.||Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O'Riordan CR. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum Gene Ther. 1999;10:2615-2626. [PubMed] [DOI]|
|20.||Wang W, Zhou J, Xu L, Zhen Y. Antineoplastic effect of intracellular expression of a single-chain antibody directed against type IV collagenase. J Environ Pathol Toxicol Oncol. 2000;19:61-68. [PubMed]|
|21.||Li J, Wang Y, Li Q. Construction and expression of ScFv from anti-human gastric cancer McAb 3H11. Zhonghua Zhongliu Zazhi. 1998;20:85-87.|
|22.||Wei XC, Wang XJ, Chen K, Zhang L, Liang Y, Lin XL. Killing effect of TNF-related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87. World J Gastroenterol. 2001;7:559-562. [PubMed]|
|23.||Liu DH, Zhang W, Su YP, Zhang XY, Huang YX. Construction of eukaryotic expression vector of sense and antisense VEGF165 and its expression regulation. Shijie Huaren Xiaohua Zazhi. 2001;9:886-891.|
|24.||Liu WC, Mu HX, Ren J, Zhang XY, Pan BR. Anti-tumor activity of defensin on gastric cancer cell line in vitro. Shijie Huaren Xiaohua Zazhi. 2001;9:622-626.|
|25.||Yang JT, Fang DC, Yang SM, Luo YH, Lu R, Luo KL, Liu WW. Construction of sense and antisense hTR eukaryotic expression vector. Shijie Huaren Xiaohua Zazhi. 2000;8:491-493.|
|26.||Huang ZH, Qian WF, Chi DB, Jiang ZS. Apoptosis in human colorectal cancer Lovo cells induced by HSVtK/GCV system in vitro. Shijie Huaren Xiaohua Zazhi. 2001;9:194-197.|
|27.||Qian WF, Huang ZH, Chi DB. Herpes simplex virus thymidine kinase/ ganciclovir system combined with 5-FU for the treatment of experimen-tal colorectal cancer. Shijie Huaren Xiaohua Zazhi. 2001;9:190-193.|
|28.||Xu DX, Chen WS, Ye ZJ. The antisense gene of growth factor receptor reversing the malignant phenotype of human hepatoma cells. Shijie Huaren Xiaohua Zazhi. 2001;9:175-179.|
|29.||Tang YC, Li Y, Qian GX. Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy. World J Gastroenterol. 2001;7:22-27. [PubMed]|
|30.||Fan DM, Zhang XY, Chen XT, Qiao TD, Chen BJ. Preparation and immunohistologic identification of mAbs against a poor differenciated gastric cancer line MKN-46-9. Jiefangjun Yixue Zhazi. 1988;13:12-15.|
|31.||Klimka A, Matthey B, Roovers RC, Barth S, Arends JW, Engert A, Hoogenboom HR. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. Br J Cancer. 2000;83:252-260. [PubMed]|
|32.||Watkins NA, Ouwehand WH. Introduction to antibody engineering and phage display. Vox Sang. 2000;78:72-79. [PubMed] [DOI]|
|33.||Zhai W, Davies J, Shang DZ, Chan SW, Allain JP. Human recombinant single-chain antibody fragments, specific for the hypervariable region 1 of hepatitis C virus, from immune phage-display libraries. J Viral Hepat. 1999;6:115-124. [PubMed] [DOI]|
|34.||de Greeff A, van Alphen L, Smith HE. Selection of recombinant antibodies specific for pathogenic Streptococcus suis by subtractive phage display. Infect Immun. 2000;68:3949-3955. [PubMed] [DOI]|
|35.||Long MC, Jager S, Mah DC, Jebailey L, Mah MA, Masri SA, Nagata LP. Construction and characterization of a novel recombinant single-chain variable fragment antibody against Western equine encephalitis virus. Hybridoma. 2000;19:1-13. [PubMed] [DOI]|
|36.||Johns M, George AJ, Ritter MA. In vivo selection of sFv from phage display libraries. J Immunol Methods. 2000;239:137-151. [PubMed] [DOI]|
|37.||Mao S, Gao C, Lo CH, Wirsching P, Wong CH, Janda KD. Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. Proc Natl Acad Sci USA. 1999;96:6953-6958. [PubMed] [DOI]|
|38.||Kupsch JM, Tidman NH, Kang NV, Truman H, Hamilton S, Patel N, Newton Bishop JA, Leigh IM, Crowe JS. Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells. Clin Cancer Res. 1999;5:925-931. [PubMed]|
|39.||Franconi R, Roggero P, Pirazzi P, Arias FJ, Desiderio A, Bitti O, Pashkoulov D, Mattei B, Bracci L, Masenga V. Functional expression in bacteria and plants of an scFv antibody fragment against tospoviruses. Immunotechnology. 1999;4:189-201. [PubMed]|
|40.||Yi K, Chung J, Kim H, Kim I, Jung H, Kim J, Choi I, Suh P, Chung H. Expression and characterization of anti-NCA-95 scFv (CEA 79 scFv) in a prokaryotic expression vector modified to contain a Sfi I and Not I site. Hybridoma. 1999;18:243-249. [PubMed] [DOI]|
|41.||McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol. 1999;36:433-445. [PubMed] [DOI]|
|42.||Winthrop MD, DeNardo SJ, DeNardo GL. Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer. Clin Cancer Res. 1999;5:3088s-3094s. [PubMed]|
|43.||Stadler BM. Antibody production without animals. Dev Biol Stand. 1999;101:45-48. [PubMed]|
|44.||Topping KP, Hough VC, Monson JR, Greenman J. Isolation of human colorectal tumour reactive antibodies using phage display technology. Int J Oncol. 2000;16:187-195. [PubMed]|
|45.||Adams GP, Schier R. Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods. 1999;231:249-260. [PubMed] [DOI]|
|46.||Lekkerkerker A, Logtenberg T. Phage antibodies against human dendritic cell subpopulations obtained by flow cytometry-based selection on freshly isolated cells. J Immunol Methods. 1999;231:53-63. [PubMed] [DOI]|
|47.||van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem. 1998;273:12960-12966. [PubMed] [DOI]|
|48.||Yang LJ, Sui YF, Chen ZN. Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A. World J Gastroenterol. 2001;7:216-221. [PubMed]|
|49.||Cheng H, Liu YF, Zhang HZ, Shen WA, Zhang SZ. Construction and expression of anti-HCC immunotoxin of sFv-TNF-α and GFP fusion proteins. Shijie Huaren Xiaohua Zazhi. 2001;9:640-644.|
|50.||Rodenburg CM, Mernaugh R, Bilbao G, Khazaeli MB. Production of a single chain anti-CEA antibody from the hybridoma cell line T84.66 using a modified colony-lift selection procedure to detect antigen-positive ScFv bacterial clones. Hybridoma. 1998;17:1-8. [PubMed] [DOI]|
|51.||Yu ZC, Ding J, Nie YZ, Fan DM, Zhang XY. Preparation of single chain variable fragment of MG(7) mAb by phage display technology. World J Gastroenterol. 2001;7:510-514. [PubMed]|
|52.||Darimont BD. The Hsp90 chaperone complex A potential target for cancer therapy. World J Gastroenterol. 1999;5:195-198. [PubMed]|
|53.||Bi WX, Xu SD, Zhang PH, Kong F. Antitumoral activity of low density lipoprotein-aclacinomycin complex in mice bearing H(22) tumor. World J Gastroenterol. 2000;6:140-142. [PubMed]|
|54.||Yang CQ, Wang JY, Fang GT, Liu JJ, Guo JS. A comparison between intravenous and peritoneal route on liver targeted uptake and expression of plasmid delivered by Glyco-poly-l-lysine. World J Gastroenterol. 2000;6:508-512. [PubMed]|
|55.||Chen YP, Zhang L, Lu QS, Feng XR, Luo KX. Lactosamination of liposomes and hepatotropic targeting research. World J Gastroenterol. 2000;6:593-596. [PubMed]|
|56.||He Y, Zhou J, Wu JS, Dou KF. Inhibitory effects of EGFR antisense oligodeox ynucleotide in human colorectal cancer cell line. World J Gastroenterol. 2000;6:747-749. [PubMed]|
|57.||Wang XW, Yuan JH, Zhang RG, Guo LX, Xie Y, Xie H. Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice. World J Gastroenterol. 2001;7:345-351. [PubMed]|
|58.||Wang L, Lu W, Chen YG, Zhou XM, Gu JR. Comparison of gene expression between normal colon mucosa and colon carcinoma by means of messenger RNA differential display. World J Gastroenterol. 1999;5:533-534. [PubMed]|
|59.||Kong XB, Yang ZK, Liang LJ, Huang JF, Lin HL. Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication. World J Gastroenterol. 2000;6:134-135. [PubMed]|
|60.||Qin LL, Su JJ, Li Y, Yang C, Ban KC, Yian RQ. Expression of IGF- II, p53, p21 and HBxAg in precancerous events of hepatocarcinogenesis induced by AFB1 and/or HBV in tree shrews. World J Gastroenterol. 2000;6:138-139. [PubMed]|
|61.||Li J, Feng CW, Zhao ZG, Zhou Q, Wang LD. A preliminary study on ras protein expression in human esophageal cancer and precancerous lesions. World J Gastroenterol. 2000;6:278-280. [PubMed]|
|62.||Xue JT, Wu J, Meng L, Dong ZW, Shou CC. Expression of VEGF(121) in gastric carcinoma MGC803 cell line. World J Gastroenterol. 2000;6:281-283. [PubMed]|
|63.||Xu AG, Li SG, Liu JH, Gan AH. The function of apoptosis and protein expression of bcl2, p53 and C-myc in the development of gastric cancer. World J Gastroenterol. 2000;6:27-33.|
|64.||Li JY, Huang Y, Lin MF. Clinical evaluation of several tumor mark-ers in the diagnosis of primary hepatic cancer. World J Gastroenterol. 2000;6:39-41.|
|65.||Lin GY, Chen ZL, Lu CM, Li Y, Wang J, Ping XJ, Huang R. Immu-nohistochemical study on p53, Hrasp21, cerbB2 protein and PCNA expression in tumor tissues of Han and minority ethnic patients with primary hepatic carcinoma in Xinjiang. World J Gastroenterol. 2000;6:53-58.|
|66.||Fan ZR, Yang DH, Cui J, Qin HR, Huang CC. Expression of insulin like growth factor II and its receptor in hepatocellular carcinogenesis. World J Gastroenterol. 2001;7:285-288. [PubMed]|
|67.||Zheng CX, Zhan WH, Zhao JZ, Zheng D, Wang DP, He YL, Zheng ZQ. The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer. World J Gastroenterol. 2001;7:431-434. [PubMed]|
|68.||Xu AG, Li SG, Liu JH, Gan AH. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. World J Gastroenterol. 2001;7:403-406. [PubMed]|
|69.||Li XG, Song JD, Wang YQ. Differential expression of a novel colorectal cancer differentiation-related gene in colorectal cancer. World J Gastroenterol. 2001;7:551-554. [PubMed]|
|70.||Chen QK, Yuan SZ, Zeng ZY, Huang ZQ. Tumoricidal activation of murine resident peritoneal macrophages on pancreaticcarcinoma by interleukin-2 and monoclonal antibodies. World J Gastroenterol. 2000;6:287-289. [PubMed]|